LifeVantage (LFVN) Competitors $19.97 +3.52 (+21.40%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends LFVN vs. REPL, PAHC, ETNB, TYRA, DNTH, PLRX, CRON, RLAY, ERAS, and LENZShould you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Replimune Group (REPL), Phibro Animal Health (PAHC), 89bio (ETNB), Tyra Biosciences (TYRA), Dianthus Therapeutics (DNTH), Pliant Therapeutics (PLRX), Cronos Group (CRON), Relay Therapeutics (RLAY), Erasca (ERAS), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. LifeVantage vs. Replimune Group Phibro Animal Health 89bio Tyra Biosciences Dianthus Therapeutics Pliant Therapeutics Cronos Group Relay Therapeutics Erasca LENZ Therapeutics LifeVantage (NASDAQ:LFVN) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability. Do institutionals & insiders hold more shares of LFVN or REPL? 35.3% of LifeVantage shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 20.7% of LifeVantage shares are owned by insiders. Comparatively, 8.8% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, LFVN or REPL? LifeVantage has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifeVantage$196.01M1.25$2.94M$0.3261.34Replimune GroupN/AN/A-$215.79M-$3.05-3.73 Do analysts recommend LFVN or REPL? LifeVantage presently has a consensus target price of $26.00, suggesting a potential upside of 32.45%. Replimune Group has a consensus target price of $17.29, suggesting a potential upside of 51.76%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts plainly believe Replimune Group is more favorable than LifeVantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LifeVantage 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is LFVN or REPL more profitable? LifeVantage has a net margin of 2.11% compared to Replimune Group's net margin of 0.00%. LifeVantage's return on equity of 29.24% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets LifeVantage2.11% 29.24% 12.82% Replimune Group N/A -53.12%-41.49% Which has more risk & volatility, LFVN or REPL? LifeVantage has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Does the MarketBeat Community favor LFVN or REPL? LifeVantage received 57 more outperform votes than Replimune Group when rated by MarketBeat users. Likewise, 77.89% of users gave LifeVantage an outperform vote while only 63.46% of users gave Replimune Group an outperform vote. CompanyUnderperformOutperformLifeVantageOutperform Votes22277.89% Underperform Votes6322.11% Replimune GroupOutperform Votes16563.46% Underperform Votes9536.54% Does the media refer more to LFVN or REPL? In the previous week, LifeVantage had 3 more articles in the media than Replimune Group. MarketBeat recorded 5 mentions for LifeVantage and 2 mentions for Replimune Group. Replimune Group's average media sentiment score of 1.14 beat LifeVantage's score of 0.59 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeVantage 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLifeVantage beats Replimune Group on 11 of the 18 factors compared between the two stocks. Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Get LifeVantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifeVantagePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$245.87M$6.63B$5.27B$9.00BDividend Yield0.91%2.91%5.30%4.03%P/E Ratio61.3510.5087.3517.17Price / Sales1.25199.081,116.75124.32Price / Cash18.1957.0443.1237.81Price / Book9.585.105.175.04Net Income$2.94M$153.18M$121.67M$227.05M7 Day Performance11.98%2.31%2.84%1.25%1 Month Performance34.36%-2.64%19.32%1.38%1 Year Performance243.78%0.33%27.78%15.52% LifeVantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifeVantage3.8638 of 5 stars$19.97+21.4%$26.00+30.2%+191.2%$250.12M$196.01M62.41260Gap UpHigh Trading VolumeREPLReplimune Group4.0791 of 5 stars$12.31-2.5%$17.29+40.4%+31.6%$842.21MN/A-4.04210Positive NewsPAHCPhibro Animal Health3.8229 of 5 stars$20.60+0.4%$20.50-0.5%+83.0%$834.36M$1.05B47.911,940ETNB89bio2.0738 of 5 stars$7.84-1.5%$30.33+286.9%-35.8%$832.03MN/A-2.6940Positive NewsTYRATyra Biosciences2.3507 of 5 stars$16.15+3.3%$31.00+92.0%+37.4%$817.24MN/A-10.0320Analyst ForecastNews CoverageDNTHDianthus Therapeutics1.5763 of 5 stars$27.24+8.4%$46.43+70.4%+99.0%$806.22M$5.37M-10.9080Positive NewsPLRXPliant Therapeutics3.5368 of 5 stars$13.24-2.1%$40.50+205.9%-25.7%$805.71M$1.58M-3.9690News CoverageCRONCronos Group2.201 of 5 stars$2.06-0.5%$3.00+45.6%-7.3%$787.53M$111.23M-15.85356Positive NewsRLAYRelay Therapeutics2.5022 of 5 stars$4.61+4.3%$20.50+344.7%-59.8%$771.64M$10.01M-1.77304Insider TradeERASErasca2.6837 of 5 stars$2.70-1.5%$5.88+117.6%+34.8%$763.36MN/A-3.25126Analyst UpgradeNews CoveragePositive NewsLENZLENZ Therapeutics2.0504 of 5 stars$27.65-2.8%$35.40+28.0%N/A$760.40MN/A0.00110 Related Companies and Tools Related Companies Replimune Group Competitors Phibro Animal Health Competitors 89bio Competitors Tyra Biosciences Competitors Dianthus Therapeutics Competitors Pliant Therapeutics Competitors Cronos Group Competitors Relay Therapeutics Competitors Erasca Competitors LENZ Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LFVN) was last updated on 1/8/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LifeVantage Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share LifeVantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
